相似文献
1
Ability of recombinant interferon gamma in vitro to restore the defective polymorphonuclear-cell- but not lymphocyte-mediated cytotoxic activities in patients with myelodysplastic syndromes.
Cancer Immunol Immunother. 1992;34(6):414-8. doi: 10.1007/BF01741753.
2
Defective antibody-dependent and lectin-induced polymorphonuclear cytotoxicity in patients with myelodysplastic syndromes.
Haematologica. 1990 Jan-Feb;75(1):46-9.
3
Deficiency of lymphocyte lectin-dependent cytotoxicity in myelodysplastic syndromes.
Acta Haematol. 1989;82(1):1-6. doi: 10.1159/000205269.
4
Release of natural killer cytotoxic factor in patients with lymphoproliferative disease of granular lymphocytes.
Leuk Res. 1989;13(4):315-22. doi: 10.1016/0145-2126(89)90068-4.
5
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
Blood. 2014 May 8;123(19):3016-26. doi: 10.1182/blood-2013-10-533398. Epub 2014 Mar 20.
6
Effect of recombinant human interferons on NK and K cell activities of gnotobiotic miniature swine.
Prog Clin Biol Res. 1985;181:329-32.
7
Augmentation of antibody-dependent cellular cytotoxicity of polymorphonuclear leukocytes by interferon-gamma: mechanism dependent on enhancement of Fc receptor expression and increased release of activated oxygens.
Chem Pharm Bull (Tokyo). 1987 Apr;35(4):1571-8. doi: 10.1248/cpb.35.1571.
8
Defective mitogen-induced cellular cytotoxicity in myelodysplastic syndromes. Recovery after alpha-interferon administration.
Anticancer Res. 1991 Mar-Apr;11(2):685-9.
9
Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.
Haematologica. 2008 Mar;93(3):381-9. doi: 10.3324/haematol.11812. Epub 2008 Feb 11.
10
The role of interferon-gamma in the immunotherapy of neuroblastoma.
Prog Clin Biol Res. 1991;366:401-7.
引用本文的文献
1
CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients.
Oncotarget. 2015 Apr 30;6(12):10592-603. doi: 10.18632/oncotarget.3547.
本文引用的文献
1
Immune interferon: a pleiotropic lymphokine with multiple effects.
Immunol Today. 1985 Apr;6(4):131-6. doi: 10.1016/0167-5699(85)90080-5.
2
Impaired T-cell and NK-cell function in patients with preleukemia.
Blut. 1982 Oct;45(4):243-8. doi: 10.1007/BF00320191.
3
PHA-ICC, ADCC and NK in patients with ANLL in CR: human fibroblastic interferon fails to increase NK-active cell frequency.
Leuk Res. 1984;8(5):885-91. doi: 10.1016/0145-2126(84)90109-7.
4
Surface markers of human natural killer cells as analyzed in a modified single cell cytotoxicity assay on poly-L-lysine coated cover slips.
J Immunol Methods. 1983 Aug 12;62(1):87-99. doi: 10.1016/0022-1759(83)90114-x.
5
Blood neutrophil function in primary myelodysplastic syndromes.
Br J Haematol. 1983 Oct;55(2):217-27. doi: 10.1111/j.1365-2141.1983.tb01241.x.
6
7
Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells.
Blood. 1983 Mar;61(3):596-9.
8
Interferon enhances the antibody-dependent cellular cytotoxicity (ADCC) of human polymorphonuclear leukocytes.
J Immunol. 1981 Oct;127(4):1585-8.
9
Interferon activation of "pre-spontaneous killer" (pre-SK) cells and alteration in kinetics of lysis of both "pre-SK" and active SK cells.
J Immunol. 1980 May;124(5):2157-61.
10
Immunoregulatory abnormalities in myelodysplastic disorders.
Am J Hematol. 1986 May;22(1):17-26. doi: 10.1002/ajh.2830220104.
Zotero 插件